Compare · CI vs OPGN
CI vs OPGN
Side-by-side comparison of The Cigna Group (CI) and OpGen Inc. (OPGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and OPGN operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.61B, about 1996.6x OPGN ($38.4M).
- Over the past year, CI is down 7.0% and OPGN is up 0.0% - OPGN leads by 7.0 points.
- CI has hit the wire 4 times in the past 4 weeks while OPGN has been quiet.
- CI has more recent analyst coverage (25 ratings vs 0 for OPGN).
- Company
- The Cigna Group
- OpGen Inc.
- Price
- $289.50+0.00%
- $1.96-14.04%
- Market cap
- $76.61B
- $38.4M
- 1M return
- +1.94%
- +0.00%
- 1Y return
- -7.00%
- +0.00%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
OpGen Inc.
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is based in Rockville, Maryland.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest OPGN
- Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments
- SEC Form NT 10-K filed by OpGen Inc.
- OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
- OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form DEF 14A filed by OpGen Inc.
- SEC Form PRE 14A filed by OpGen Inc.
- OpGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- OpGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits
- New insider Bonte Christian-Laurent claimed ownership of 28,571 shares (SEC Form 3)
- OpGen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits